Ľubovník bodkovaný – Hypericum perforatum

Literatúra

  1. Tian J1, et al. Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L. Sci Rep. (2014)
  2. Brockmöller J1, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry. (1997)
  3. Kerb R1, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother. (1996)
  4. Treiber K1, et al. Hyperforin activates nonselective cation channels (NSCCs). Br J Pharmacol. (2005)
  5. Yang B1, Samson WK, Ferguson AV. Excitatory effects of orexin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C. J Neurosci. (2003)
  6. Leuner K1, et al. Hyperforin–a key constituent of St. John’s wort specifically activates TRPC6 channels. FASEB J. (2007)
  7. Leuner K1, et al. Hyperforin modulates dendritic spine morphology in hippocampal pyramidal neurons by activating Ca(2+) -permeable TRPC6 channels. Hippocampus. (2013)
  8. Gobbi M1, et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol. (1999)
  9. Singer A1, Wonnemann M, Müller WE. Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther. (1999)
  10. Chatterjee SS1, et al. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci. (1998)
  11. Yoshitake T1, et al. Hypericum perforatum L (St John’s wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol. (2004)
  12. Russo E1, et al. Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res. (2014)
  13. Staffeldt B1, et al. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol. (1994)
  14. Biber A1, et al. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry. (1998)
  15. Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John’s wort drug interactions.. Curr Drug Metab. (2008)
  16. Goodwin B, et al. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor.. Mol Pharmacol. (2001)
  17. Chen Y, et al. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.. J Pharmacol Exp Ther. (2004)
  18. Rahimi R, Abdollahi M. An update on the ability of St. John’s wort to affect the metabolism of other drugs.. Expert Opin Drug Metab Toxicol. (2012)
  19. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression.. J Pharmacol Exp Ther. (2000)
  20. Bauer S, et al. Differential effects of Saint John’s Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers.. Eur J Clin Pharmacol. (2002)
  21. Wang LS, et al. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.. Clin Pharmacol Ther. (2004)
  22. Smith P, et al. The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate.. Pharmacotherapy. (2004)
  23. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein.. Drug Metab Rev. (2004)
  24. Wang Z, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity.. Clin Pharmacol Ther. (2001)
  25. Wenk M, Todesco L, Krähenbühl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females.. Br J Clin Pharmacol. (2004)
  26. Imai H, et al. The recovery time-course of CYP3A after induction by St John’s wort administration. Br J Clin Pharmacol. (2008)
  27. Chen XW, et al. Clinical herbal interactions with conventional drugs: from molecules to maladies.. Curr Med Chem. (2011)
  28. Morimoto T, et al. Effect of St. John’s wort on the pharmacokinetics of theophylline in healthy volunteers.. J Clin Pharmacol. (2004)
  29. Jiang X, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.. Br J Clin Pharmacol. (2004)
  30. Schulz V. Safety of St. John’s Wort extract compared to synthetic antidepressants.. Phytomedicine. (2006)
  31. Wang XD, et al. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study.. J Chromatogr B Analyt Technol Biomed Life Sci. (2007)
  32. Tannergren C, et al. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.. Clin Pharmacol Ther. (2004)
  33. Sugimoto K, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin.. Clin Pharmacol Ther. (2001)
  34. Eggertsen R, Andreasson A, Andrén L. Effects of treatment with a commercially available St John’s Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin.. Scand J Prim Health Care. (2007)
  35. Wang LS, et al. The influence of St John’s Wort on CYP2C19 activity with respect to genotype.. J Clin Pharmacol. (2004)
  36. Mannel M. Drug interactions with St John’s wort : mechanisms and clinical implications.. Drug Saf. (2004)
  37. Hall SD, et al. The interaction between St John’s wort and an oral contraceptive.. Clin Pharmacol Ther. (2003)
  38. Di YM, et al. Clinical drugs that interact with St. John’s wort and implication in drug development.. Curr Pharm Des. (2008)
  39. Bauer S, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients.. Br J Clin Pharmacol. (2003)
  40. Mathijssen RH, et al. Effects of St. John’s wort on irinotecan metabolism.. J Natl Cancer Inst. (2002)
  41. Zhou S, et al. Pharmacokinetic interactions of drugs with St John’s wort.. J Psychopharmacol. (2004)
  42. Jakobs D1, et al. Downregulation of β1 -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John’s wort. J Pharm Pharmacol. (2013)
  43. Prenner L1, et al. Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry. (2007)
  44. Simbrey K1, Winterhoff H, Butterweck V. Extracts of St. John’s wort and various constituents affect beta-adrenergic binding in rat frontal cortex. Life Sci. (2004)
  45. De Marchis GM1, et al. Vitamin E reduces antidepressant-related beta-adrenoceptor down-regulation in cultured cells. Comparable effects on St. John’s wort and tricyclic antidepressant treatment. Planta Med. (2006)
  46. Müller WE1, et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. (1997)
  47. Müller WE1, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry. (1998)
  48. Müller WE. Current St John’s wort research from mode of action to clinical efficacy. Pharmacol Res. (2003)
  49. Carboni E1, et al. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem. (1990)
  50. Mollenhauer HH1, Morré DJ, Rowe LD. Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim Biophys Acta. (1990)
  51. Suzuki O, et al. Inhibition of monoamine oxidase by hypericin. Planta Med. (1984)
  52. Bladt S1, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol. (1994)
  53. Thiede HM1, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol. (1994)
  54. Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev. (2008)
  55. Linde K, et al. St John’s wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry. (2005)
  56. Gelenberg AJ, et al. The effectiveness of St. John’s Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry. (2004)
  57. Brenner R, Madhusoodanan S, Pawlowska M. Efficacy of continuation treatment with hypericum perforatum in depression. J Clin Psychiatry. (2002)
  58. Fava M, et al. A Double-blind, randomized trial of St John’s wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. (2005)
  59. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA. (2002)
  60. Kasper S, et al. Superior efficacy of St John’s wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial {ISRCTN77277298}. BMC Med. (2006)
  61. Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study.
  62. Laakmann G, et al. St. John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. (1998)
  63. Effectiveness of St John’s Wort in Major Depression.
  64. Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry. (2001)
  65. Hänsgen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. J Geriatr Psychiatry Neurol. (1994)
  66. The Ham D6 is more homogenous and as sensitive as the Ham D17.
  67. Lecrubier Y, et al. Efficacy of St. John’s wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. (2002)
  68. Uebelhack R, et al. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther. (2004)
  69. Schrader E. Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. (2000)
  70. Behnke K, et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther. (2002)
  71. Bjerkenstedt L, et al. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci. (2005)
  72. Brenner R, et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther. (2000)
  73. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry. (2005)
  74. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry. (2006)
  75. St John’s wort or sertraline? Randomized controlled trial in primary care.
  76. Harrer G, Hübner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol. (1994)
  77. Harrer G, et al. Comparison of equivalence between the St. John’s wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung. (1999)
  78. Vitiello B, et al. Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. J Clin Psychopharmacol. (2005)
  79. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis.
  80. Moreno RA, et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev Bras Psiquiatr. (2006)
  81. Anghelescu IG, et al. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Pharmacopsychiatry. (2006)
  82. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ. (1999)
  83. Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial.
  84. Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St. John’s wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. (1997)
  85. Wheatley D. LI 160, an extract of St. John’s wort, versus amitriptyline in mildly to moderately depressed outpatients–a controlled 6-week clinical trial. Pharmacopsychiatry. (1997)